What are the key findings of this study?

June 12, 2026Neurology

Compassionate Use of Kv7.2/7.3 Potassium Channel Activator Opakalim (BHV-7000) in a Child with KCNQ2 Developmental and Epileptic Encephalopathy (P10-11.002)

View Full Paper

Ask AI

Bookmark

Key result

Opakalim provides compassionate treatment for a child with KCNQ2 developmental and epileptic encephalopathy.

Authors

HOHeather OlsonBoston Children's Hospital EMEorna Maguire-LobosBoston Children's Hospital KMKathryn MansourBoston Children's Hospital

Discussion

Member takes

Implication

Hypothesis-generating for opakalim in KCNQ2-DEE; should not change practice pending controlled trials.

Cite This Study

Olson et al. (2026) studied this question. Opakalim, a Kv7.2/7.3 potassium channel activator, was used compassionately to treat a child with KCNQ2 developmental and epileptic encephalopathy.

synapsesocial.com/papers/6a2bd1056550ea4541ffe830 https://doi.org/10.1212/wnl.0000000000216347

View Full Paper

Ask AI

Bookmark

Compassionate Use of Kv7.2/7.3 Potassium Channel Activator Opakalim (BHV-7000) in a Child with KCNQ2 Developmental and Epileptic Encephalopathy (P10-11.002)

Discussion

Member takes

Implication

Cite This Study

Compassionate Use of Kv7.2/7.3 Potassium Channel Activator Opakalim (BHV-7000) in a Child with KCNQ2 Developmental and Epileptic Encephalopathy (P10-11.002)

Discussion

Member takes

Implication

Cite This Study

Also Consider

Also Consider